Speaker(s): 

William Leach, MD, Fellow, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• understand treatment for Cryptococcal Pneumonia in setting of multiple sclerosis
• identify the classification of cryptococcal pneumonia severity
• discuss the treatment of cryptococcal pneumonia prior to initiation of Ocrelizumab

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Stanley Martin, MD, Julie Gombert, RN and Bradley Lauver, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commerical Support for this Session

None.